Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
TEVA PHARMACEUTICALS USA, INC. v. AZAR, II et al
Case Number:
1:18-cv-02394
Court:
Nature of Suit:
Administrative Procedure Act/Review or Appeal of Agency Decision
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
February 27, 2019
Teva Can't Fight FDA's New Generic-Exclusivity Policy: Judge
Teva Pharmaceuticals' closely watched challenge to the U.S. Food and Drug Administration's new policy on generic-drug exclusivity is premature because the company may have forfeited exclusivity under other policies, a D.C. federal judge ruled Tuesday.
-
November 05, 2018
Teva Suit Built On 'Tottering Tower Of Conjecture,' FDA Says
Teva Pharmaceuticals' high-profile challenge to a new U.S. Food and Drug Administration policy on generic-drug exclusivity is wildly speculative and has virtually no chance of succeeding, the FDA told a D.C. federal judge Friday.
-
October 18, 2018
Teva Sues FDA Over New Stance On Generic-Drug Exclusivity
A new U.S. Food and Drug Administration policy threatens to deprive generic-drug makers of lucrative exclusivity even when they expose themselves to litigation by challenging patents for brand-name drugs, Teva Pharmaceuticals said in a lawsuit filed Wednesday.